Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Apatinib

Oxaliplatin

In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.

Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.

ApatinibMesylateTablets

We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Ttherapy for Locally Advanced Gastric Cancer(cT2-4/N+M0)

Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Apatinib Combined With Oxaliplatin and Gimeracil and Oteracil Porassium Capsules Neoadjuvant Therapy for Locally Advanced Gastric Cance: A Multicentre, One-armed, Clinical Pilot Trial

Radical surgical resection rate is defined as the rate of R0 resection

Briefly, pathCR (Pathological complete rate) was defined as an absence of carcinoma cells in the primary site, and pathologic partial response (pathPR) was defined as less than 10% residual carcinoma cells in the specimen.

according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery.

Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.

Defined as the event observed within 30 days after surgery.

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer	NCT03192735	Apatinib Combin... SOX Neoadjuvant The... Locally Advance...	ApatinibMesylat...	18 Years - 75 Years	Fujian Medical University
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer	NCT03192735	Apatinib Combin... SOX Neoadjuvant The... Locally Advance...	ApatinibMesylat...	18 Years - 75 Years	Fujian Medical University
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer	NCT03192735	Apatinib Combin... SOX Neoadjuvant The... Locally Advance...	ApatinibMesylat...	18 Years - 75 Years	Fujian Medical University

Spots Global Cancer Trial Database for apatinib combined